Siloxane Import Conditions and Zuranolone Proposal

Summary#

• The Canada Gazette published Ministerial Condition No. 22407 under the Canadian Environmental Protection Act, 1999, allowing the manufacture or import of the chemical siloxanes and silicones, di‑Me, Me 3-(2-oxiranylmethoxy)propyl, Me 3,3,3-trifluoropropyl (CAS RN 3086114-77-1) but only if certain conditions and record-keeping rules are followed; these conditions took effect January 27, 2026.
• Separately, Health Canada published a notice proposing to add zuranolone to Schedule IV of the Controlled Drugs and Substances Act (a proposal, not yet law). Public comments are invited until April 18, 2026.

What it does#

• Ministerial condition for the siloxane chemical (effective January 27, 2026):

  • Permits the named company (the “notifier”) to manufacture or import the substance, but only under specific conditions.
  • Requires immediate action and notification if the substance is released to the environment.
  • Requires the notifier to inform any person they transfer the substance to, and to get written confirmation that the recipient agrees to follow the conditions.
  • Requires detailed record-keeping on uses, quantities, transfers and recipients; records must be kept in Canada for at least five years and be electronically readable if stored electronically.

• Health Canada proposal on zuranolone:

  • Proposes to list zuranolone on Schedule IV of the Controlled Drugs and Substances Act because of concerns about misuse and dependence.
  • If scheduled, activities such as producing, selling, importing, exporting or transporting the drug would generally require a controlled substances licence and shipment permits; research or clinical trials would need exemptions.
  • The drug would remain prescription-only; Health Canada proposes a transitional labelling period to ease supply chain effects.
  • This is a consultation — not a final decision. Comments are open until April 18, 2026.

Who's affected#

• CEPA ministerial condition:

  • The notifier (the company that submitted information on December 12, 2025) and any other firms that receive, handle, import or distribute the named chemical.
  • Regulators and local emergency responders who may be notified of releases.

• Zuranolone proposal:

  • People prescribed zuranolone, their prescribers and pharmacies (availability stays prescription-only but oversight would increase).
  • Drug manufacturers, importers, exporters, distributors and clinical researchers who work with the drug.
  • Law enforcement and border agencies would get additional tools to control illegal diversion.

If any point above is unclear from the notice (for example, the public notice does not name the notifier company), the Gazette item does not provide that detail.

Why it matters#

• For the siloxane chemical: companies that make, import or pass on this substance must follow specific safety, notification and record rules. That can change how the product is handled, traced and reported, and it gives regulators clearer information if there is a release to the environment.
• For zuranolone: scheduling would increase regulatory oversight to reduce misuse and illegal diversion. That affects researchers and parts of the drug supply chain and could change paperwork, permits and labelling requirements even though the medicine would still be available only by prescription. The outcome could influence access, clinical research, and enforcement actions.